Jiangsu Hengrui Pharmaceuticals Co Ltd – Investor Focus in 2026
Company Overview
Jiangsu Hengrui Pharmaceuticals Co Ltd is a health‑care enterprise headquartered in Lianyungang, China. The company develops, manufactures, and markets a broad spectrum of pharmaceutical products, including anti‑tumor drugs, pain‑killers, anti‑infection medicines, and packaging materials such as aluminum foil. It is listed on the Shanghai Stock Exchange and trades in Hong Kong under the ticker on the Hong Kong Stock Exchange.
- Sector: Health Care
- Industry: Pharmaceuticals
- Currency: HKD
- Market Capitalisation: 410 040 000 000 HKD
- Recent Share Price (29 Apr 2026): 65 HKD
- 52‑Week Range (2025): 95.2 HKD (high) – 50.2 HKD (low)
Fund Positioning – 2026 First‑Quarter Reports
Three actively managed mutual funds disclosed their 2026 Q1 performance on 1 May 2026. Jiangsu Hengrui Pharmaceuticals appears among the top holdings in each fund, signalling continued investor interest in the company.
| Fund | Fund Type | Manager(s) | 2026 Q1 Profit (HKD) | Net‑Value Growth Rate | Fund Size (end‑Q1) | Key Holdings (Top‑10) |
|---|---|---|---|---|---|---|
| 中欧鑫享鼎益一年持有混合A (015098) | 偏债混合 | 华李成, 袁田 | 1 385 400 | 1.62 % | 748 879 000 | 宁德时代, 贵州茅台, 海康威视, 五粮液, 厦门象屿, 恒瑞医药, 万华化学, 药明康德 |
| 汇添富医疗积极成长一年持有混合A (009664) | 偏股混合 | 郑磊 | 53 812 100 | 3.05 % | 1 687 000 000 | 同上，含 恒瑞医药 |
| 国泰海通君得鑫2年持有混合A (952009) | 偏股混合 | 陈思靖, 李子波, 范杨 | 3 136 700 | 0.68 % | 371 000 000 | 东山精密, 迈为股份, 扬杰科技, 丰倍生物, 江丰电子, 恒瑞医药, 华天科技, 东方电气, 阿特斯, 纳芯微 |
Note: “恒瑞医药” refers to Jiangsu Hengrui Pharmaceuticals Co Ltd.
Fund Performance Highlights
- 中欧鑫享鼎益一年持有混合A reported a modest 1.62 % net‑value growth in Q1, with a profit of 1.385 million HKD, and a fund size of 748.88 million HKD.
- 汇添富医疗积极成长一年持有混合A achieved a higher 3.05 % net‑value increase, generating 53.812 million HKD in profit and managing a fund of 1.687 billion HKD.
- 国泰海通君得鑫2年持有混合A posted a 0.68 % increase, yielding 3.137 million HKD profit and overseeing 371 million HKD in assets.
All three funds maintained a positive outlook on the medical‑drug sector, citing robust performance in innovation‑driven and outpatient‑care segments. Jiangsu Hengrui Pharmaceuticals’ inclusion among the top holdings reflects its perceived value within these investment themes.
Market Context
The broader pharmaceutical industry continues to exhibit growth driven by anti‑tumor therapies, pain management solutions, and emerging biopharmaceuticals. Jiangsu Hengrui’s product portfolio aligns with these market trends, contributing to its attractiveness among funds focusing on medical‑drug exposure.
Conclusion
The 2026 first‑quarter disclosures from multiple actively managed funds demonstrate sustained investor confidence in Jiangsu Hengrui Pharmaceuticals. The company’s consistent presence among top holdings, coupled with its solid financial fundamentals and positioning within high‑growth therapeutic areas, underscores its relevance to institutional portfolios targeting the Chinese pharmaceutical market.
